Personalis, Inc. to Present at the 2019 Immuno-Oncology 360 Conference in New York Menlo Park, CA – February 5, 2019 – Personalis, Inc., a leader in advanced genomics for precision oncology, today announced that they are scheduled to present at the upcoming Immuno-Oncology 360° Conference in New York on Thursday, February 7, 2019 at [...]
RepertoireID An analytical module of the ImmunoID NeXT Platform Comprehensive Profiling of the TCR Repertoire T-cells are one of two types of lymphocytes (the other being B-cells) that are active cellular participants in the adaptive immune system. T-cells express T-cell receptors (TCRs) on their surface, and these receptors function [...]
2018 SITC: More Sensitive Identification of T-cell Receptor Beta Arrangements with an Augmented Transcriptome Method With the increase in development and use of immunotherapies, there is also an increasing need for comprehensive immuno-genomic profiling of tumors to identify new potential biomarkers. This includes profiling of the T-cell receptor (TCR), which has traditionally not been [...]
Personalis Appoints Biotech Industry Executive Clinton Musil as Chief Business Officer Menlo Park, CA – January 3, 2019 – Personalis, Inc., a leader in advanced genomics for precision oncology, today announced the appointment of Clinton Musil as Chief Business Officer. Mr. Musil will focus initially on financing strategy. As a member of Personalis’ [...]
Clinton Musil joined Personalis in January 2019 as Chief Business Officer. Mr. Musil previously worked at ARMO Biosciences, where he oversaw the Company’s $147 million initial public offering and $1.6 billion sale to Eli Lilly. Clinton has expertise in corporate finance and mergers and acquisitions (M&A) from the healthcare industry, including raising several billion dollars [...]
2018 SITC: Improving Neoantigen Identification for Therapeutic and Diagnostic Use in Immuno-Oncology Using Mass Spectrometry and Machine Learning Neoantigens are increasingly critical in immuno-oncology as therapeutic targets for neoantigen-based personalized cancer vaccines (PCVs) and as potential biomarkers for immunotherapy response. However, the methods for identifying which neoepitopes are more likely to provoke an immune [...]
2018 AACR: Methods of Improving Accuracy of Neoantigen Identification for Therapeutic and Diagnostic Use in Immuno-oncology Neoantigens are increasingly critical in immuno-oncology as a therapeutic target for neoantigen-based personalized cancer vaccines and as a potential biomarker for immunotherapy response. However, the methods for identifying which neoepitopes are more likely to provoke an immune response remains [...]
2018 AACR: Supporting Neoantigen Discovery and Monitoring in Plasma Through Analytical Validation of a Deep Augmented Content Enhanced (ACE) Exome Neoantigens are increasingly critical in immuno-oncology as a therapeutic target for neoantigen-based personalized cancer vaccines and as a potential biomarker for immunotherapy response. An important step in identifying neoantigens is comprehensive exome and transcriptome [...]
2018 AACR: Molecular Profiling of Anti-PD-1 Treated Melanoma Patients Reveals Importance of Assessing Neoantigen Burden and Tumor Escape Mechanisms for Clinical Treatment Despite the remarkable response of some melanoma patients to checkpoint inhibitor therapy, significant numbers of patients do not achieve complete response. To understand this differential response, there is an increasing interest in [...]
2018 AACR: Deconvolution of diverse immune cell populations within tumors using ACE Transcriptome Comprehensive tumor immuno-genomic characterization is becoming an important tool for identifying new biomarkers correlated with patient response to immunotherapy. Both the abundance and composition of tumor-infiltrating immune cells have been associated with tumor progression and patient outcome. There is interest in [...]
